Hospira

Hospira
Share
Hospira is the world’s leading provider of injectable drugs and infusion technologies. Through its broad, integrated portfolio, Hospira is uniquely positioned to Advance Wellness™ by improving patient and caregiver safety while reducing healthcare costs. The company is headquartered in Lake Forest, IL, and has approximately 14,000 employees. Learn more at www.hospira.com.

Hospira

 •  August 27, 2015

Next-generation infusion system offers expanded drug library and EMR interoperability
Hospira, Inc. (NYSE: HSP), the world's leading provider of injectable drugs and infusion technologies, today announced the first installation of the Plum 360™ infusion system with Hospira MedNet™, at Shannon Medical Center in San Angelo, Texas. The Plum 360 ...

Hospira

 •  August 25, 2015

Hospira, Inc. (NYSE: HSP), the world's leading provider of injectable drugs and infusion technologies, andCerner (NASDAQ: CERN), a global leader in healthcare technology, today announced a commitment to advance the integration of I.V.-EMR technology. The expanded agreement strengthens both companies' ability to continue to bring innovative ...

Hospira

 •  August 20, 2015

Hospira’s Inflectra™ registered in Australia Melbourne, Australia, Aug 20, 2015 – Hospira today announced that Inflectra™ (infliximab), the first monoclonal antibody (mAb) biosimilar therapy, has been registered in Australia. This registration paves the way for the Federal Government to reduce the cost of some of the most expensive medicines on ...

Hospira

 •  August 13, 2015

LAKE FOREST, Illinois, Aug. 13, 2015 /PRNewswire/ -- Hospira, Inc. (NYSE: HSP) applauds the UK's National Institute for Health and Clinical Excellence (NICE) for developing and issuing a new adoption resource to further support the introduction of biosimilar infliximab, including Hospira's Inflectra™, allowing patients greater access to these ...

Hospira

 •  July 29, 2015

Hospira, Inc. (NYSE: HSP), the world's leading provider of injectable drugs and infusion technologies, and a global leader in biosimilars, today reported results for the second quarter ended June 30, 2015. For the second quarter of 2015, net sales were $1.2 billion, and adjusted* diluted earnings per share were $0.85. (Adjusted* measures exclude ...

Hospira

 •  July 17, 2015

Hospira, Inc. (NYSE: HSP), the world's leading provider of injectable drugs and infusion technologies, and a global leader in biosimilars, today announced it had obtained U.S. Food and Drug Administration (FDA) approval for the launch of bivalirudin for injection, a generic version of The Medicines Company's Angiomax™. Branded sales of Angiomax ...

Hospira

 •  July 15, 2015

Hospira, Inc. (NYSE: HSP), the world's leading provider of injectable drugs and infusion technologies, and a global leader in biosimilars, will release its second-quarter 2015 results on Wednesday, July 29, 2015, before the U.S. stock market open. Given the company's pending merger with Pfizer Inc., Hospira will not be holding a conference call ...

Hospira

 •  June 10, 2015

The new independent clinical study data presented at EULAR's annual congress this week adds to the growing wealth of data for Hospira's Inflectra (infliximab), the first biosimilar monoclonal antibody, which received approval from the European Commission in 2013 - Inflectra provides a potentially cost effective treatment option for people ...

Hospira

 •  June 2, 2015

Remsima™(infliximab) is the first biological medication approved by Brazil's regulator based on comparability - The medication will be marketed by Hospira, Inc. - a global leader in biosimilars
Hospira, Inc. (NYSE: HSP), a global leader in biosimilars, today announced that its partner, Celltrion – a global biopharmaceutical company – has received ...

Hospira

 •  May 13, 2015

Subject to certain closing conditions, Pfizer will acquire Hospira for $90 per share
Hospira, Inc. (NYSE: HSP), the world's leading provider of injectable drugs and infusion technologies, and a global leader in biosimilars, announced that Hospira shareholders voted in favor of the proposal to adopt the merger agreement with Pfizer Inc. at a ...